Previous 10 | Next 10 |
Nurix Therapeutics, Inc. (NASDAQ: NRIX) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 12.32% on the day to $10.12. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and...
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D.,...
2023-04-06 17:02:48 ET Gainers: Ramaco Resources ( METC ) +5% . Aemetis ( AMTX ) +5% . El Pollo Loco Holdings ( LOCO ) +5% . Independent Bank Corporation ( IBCP ) +2% . SMART Global Holdings ( SGH ) +2% . Losers: Nurix Th...
-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- FOSTER CITY, Calif. and SAN FRANCISCO, March 20, 2023 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) a...
2023-03-19 23:39:45 ET Summary NRIX announced early data at ASH last year. The company has a couple of major partnerships. They have a decent cash runway. Nurix Therapeutics ( NRIX ) works in the field of targeted protein degradation in order to attack cancer cells. ...
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D.,...
Nurix Therapeutics press release ( NASDAQ: NRIX ): Q4 GAAP EPS of -$0.87 misses by $0.10 . Revenue of $6.78M (-8.4% Y/Y) misses by $10.39M . For further details see: Nurix Therapeutics GAAP EPS of -$0.87 misses by $0.10, revenue of $6.78M misses by $10.39M
Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical programs Maintained strong financial position w...
The following slide deck was published by Nurix Therapeutics, Inc. in conjunction with this event. For further details see: Nurix Therapeutics (NRIX) Presents At 41st Annual Healthcare Conference - Slideshow
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix’s two first-in-class BTK degraders in 2023 Clinical data update planned for...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...